NASDAQ$CYRX

CryoPort Inc. · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Cryoport's Q3 2024 financial results were announced, highlighting growth in the Life Sciences Services business and improvements in gross margin and adjusted EBITDA.

Cryoport reported growth in its Life Sciences Services business, with BioStorage/BioServices revenue increasing by 12%. The company is maintaining its full-year revenue forecast of $225 million to $235 million and is on track to complete cost reduction and capital realignment strategies by year's end. A return to positive adjusted EBITDA is expected during 2025.

  • Life Sciences Services business grew by 9% in Q3 2024.
  • BioStorage/BioServices revenue increased by 12% compared to Q3 2023.
  • Gross margin improved to 46% for the services business.
  • The company reaffirms full year 2024 revenue guidance in the range of $225 million - $235 million.

Headline financials

Total Revenue

$56.7M

Previous: $56.2M+0.9%
EPS

-$0.02

Previous: -$0.31+93.5%
Global Clinical Trials Supported

691

No prior period
Phase 1 Clinical Trials

295

No prior period
Phase 2 Clinical Trials

317

No prior period
Phase 3 Clinical Trials

79

No prior period
Americas Clinical Trials

531

No prior period
EMEA Clinical Trials

112

No prior period
APAC Clinical Trials

48

No prior period
Capital Expenditures

-$12M

Previous: -$27.2M+55.8%
Free Cash Flow

-$11.2M

Previous: -$40.5M+72.3%
Net Income

$805K

Previous: -$13.3M+106.1%
Operating Income

-$16.4M

Previous: -$16.9M+2.9%
Gross Profit

$25.4M

Previous: $24.3M+4.6%
Cash & Equivalents

$44.7M

Previous: $59.5M-24.9%
Total Assets

$702M

Previous: $1B-29.9%
R&D Expense

$4.16M

Previous: $5.15M-19.3%
Stock-Based Comp

$4.84M

Previous: $5.98M-19.0%

Revenue & EPS history

CryoPort · Revenue · Quarterly

$56.7M

Q3 2024+0.9%vs Q3 2023
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

The Company reaffirms full year 2024 revenue guidance in the range of $225 million - $235 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+2.2%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+8.5%

Avg return

30 days after

49%

28 / 57 earnings

Positive

+31.6%

Q4 2013

Best reaction

-33.8%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+19.4%+33.2%+58.2%
Q4 2025+2.9%-4.7%+3.3%
Q3 2025-8.2%-7.4%+3.5%
Q1 2025+23.4%+23.3%+23.7%
Q4 2024+30.6%-7.1%+5.7%
Q3 2024-3.6%-0.9%-8.6%
Q2 2024+3.9%+10.0%+9.8%
Q1 2024-17.5%-16.7%-30.6%
Q4 2023-12.3%-7.3%+10.3%
Q3 2023+8.9%+8.4%+46.7%
Q2 2023-0.2%+1.2%-5.0%
Q1 2023+13.9%+4.5%-6.3%
Q4 2022+13.7%+9.9%+15.3%
Q3 2022-33.8%-35.7%-26.5%
Q2 2022+6.8%+5.2%-16.1%
Q1 2022-8.5%-14.6%-2.8%
Q4 2021+9.3%+7.0%+1.9%
Q3 2021-1.0%-1.2%-22.8%
Q2 2021-1.5%-3.6%+2.9%
Q1 2021+9.0%+11.6%-2.4%
Q4 2020-0.7%-11.7%-12.5%
Q3 2020+5.0%+24.2%+12.8%
Q2 2020-2.0%-5.0%+55.5%
Q1 2020+2.0%+17.0%+22.6%
Q4 2019+2.1%+0.8%-11.9%
Q3 2019+1.4%+3.9%+5.6%
Q2 2019+19.7%+24.5%+2.3%
Q1 2019+12.5%+12.5%+17.7%
Q4 2018-0.6%+6.6%+22.3%
Q3 2018-1.0%-9.4%-2.0%
Q2 2018-1.6%-14.7%-6.5%
Q1 2018+11.8%+23.0%+67.4%
Q4 2017+3.8%+6.4%-7.0%
Q3 2017-15.1%-22.9%-10.5%
Q2 2017-2.0%+3.6%+28.6%
Q1 2017+8.2%+9.0%+46.9%
Q4 2016+23.7%+9.0%+23.7%
Q2 2016-7.5%
Q1 2016+10.2%
Q4 2015-3.0%
Q3 2015+7.5%
Q2 2015-14.4%
Q1 2015-2.2%
Q4 2014+6.4%
Q3 2014-5.6%
Q4 2013+31.6%
Q3 2013-8.0%
Q2 2013+5.3%
Q1 2013+0.0%
Q4 2012-3.1%
Q3 2012-10.8%
Q2 2012-8.0%
Q1 2012-2.7%
Q1 2010+11.2%
Q3 2009+1.4%
Q2 2009-2.8%
Q1 2009+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro